Join
Live feed
·
PRReleasevia Quantisnow
Global Blood Therapeutics Inc. logo

GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease

ByQuantisnow·Wall Street's wire, on your screen.
GBT· Global Blood Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GBT (Global Blood Therapeutics Inc.) and more on Quantisnow.